Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

Many patients with obesity are at higher risk for diabetes and cardiovascular disease, so evaluating the impact of weight loss on markers of cardiovascular and metabolic risk was a key objective of the COR (Contrave Obesity Research) Phase 3 program. Results from COR-I showed that treatment with Contrave resulted in significant improvements over placebo in waist circumference, insulin resistance, HDL cholesterol, triglycerides, and hsCRP, which are well-known and accepted measures of cardiometabolic risk. Patients taking Contrave also showed significant improvements in patient-reported control of eating, including reduced food cravings and reduced difficulty resisting food cravings.

"The secondary health benefits of weight loss are critical to understanding the potential role of pharmacotherapy in managing overweight and obese patients," said Frank Greenway, M.D., Medical Director at the Pennington Center Outpatient Research Clinic and lead investigator for the study. "This study showed that treatment with Contrave has meaningful impact on markers of cardiometabolic risk, demonstrating its pote
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015   CSL Behring ... a Marketing Authorization Application (MAA) for the company,s ... IX with recombinant albumin (rIX-FP) for the prophylaxis ... Hemophilia B. Upon Swissmedic approval, rIX-FP will provide ... with dosing intervals up to 14 days. ...
(Date:7/28/2015)... July 28, 2015 Baebies, Inc. today announced ... $13 million. The oversubscribed round of financing included key ... Duke endowment), Cunning Capital, Triad, LLC, the Duke Angel ... Center. Many of Advanced Liquid Logic,s (ALL) former investors ... invested. "Rex is pleased to support ...
(Date:7/28/2015)... Fla. , July 28, 2015 ... Spectralink, the global leader in purpose-built wireless communications, ... (Bay Area Regional), a 104-bed acute-care facility in ... to implement the Voalte One™ solution on Spectralink ... "Since Spectralink named Voalte a member of ...
Breaking Medicine Technology:Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4Baebies, Inc. Raises $13 Million in Oversubscribed Round of Financing 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
(Date:7/28/2015)... ... ... Dr. Edward Buckingham and Buckingham Center for Facial Plastic Surgery, ... Coming to Austin from Philadelphia, Dr. Roy will be completing his Fellowship in facial ... annually by the American Academy of Facial Plastic and Reconstructive Surgery. , Since ...
(Date:7/28/2015)... ... 28, 2015 , ... DuPont leaders today joined public and ... more about the impact of U.S. collaborations with local partners under the U.S. ... development as an engine of broad-based economic growth in the region. , ...
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a leading global ... that enable the Internet of Things (IoT), announced its new medical panel PC, ... exceptional computing power and multitasking capabilities. The MLC 4-21 is completely fanless, and ...
(Date:7/28/2015)... ... 2015 , ... Dr. Aziz Ahmad recently gave a talk on the current ... 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center Large HR ... in colorectal surgery and has more than 35 years of experience in the surgical ...
(Date:7/28/2015)... ... ... Egg freezing is becoming an increasingly popular option for family ... Dr. Michael Kettel explained in an article from the San Diego Union-Tribune ... generations who had to make choices between their fertility and their career or personal ...
Breaking Medicine News(10 mins):Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3
... Buyout augments existing business in Philadelphia, New York ... in Tucson, Melbourne, Fla., and San Antonio, ... provider of care and care management services for,frail ... reached agreement,to acquire Care Level Management of Woodland ...
... million of required financing now in place ... - Bioniche Life Sciences,Inc. (TSX: BNC), a ... it has secured an amendment,to a pre-existing ... Office of Industry Canada that will support ...
... CHICAGO, June 25 In response to news reports ... is allegedly being treated,for medication use related to migraine, ... Migraine is not a daily headache and the use ... basis is not recommended., Pain killers are not ...
... KONG, June 25 /Xinhua-PRNewswire-FirstCall/ -- The Board ... "Company"; stock code:,8180.HK) is pleased to announce ... in entering China,s hospital management market through ... Limited and,Daopei Hospitals Group, the largest private ...
... stocked in nationwide pharmacies will provide easy access for ... ... (OTC,Bulletin Board: DSCI), a provider of advanced wound care products,announced today that ... has been cleared by the FDA for,over the counter (OTC) sales. This ...
... Executive,Director, Diana Fuentes-Michel today urged eligible nursing students ... college to immediately apply,for the 2007-08 academic year ... The deadline for applications is June 30, 2008., ... be aware of all available,resources to help them ...
Cached Medicine News:Health News:INSPIRIS Acquires Care Level Management 2Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 2Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 3Health News:Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production 4Health News:National Headache Foundation Offers Statement, Experts on Appropriate Use of Medications for Migraine Treatment 2Health News:Golden Meditech Pioneers into China's Hospital Market 2Health News:Golden Meditech Pioneers into China's Hospital Market 3Health News:Golden Meditech Pioneers into China's Hospital Market 4Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 2Health News:Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter 3Health News:Nursing Loan Forgiveness Programs -- More Applicants Needed by June 30, 2008 2
Volume: 5 ml; Volume Graduation: 1/10 ml...
... AlphaForce fills 25ml pipette in ... fatest setting. Rechargeable during use. ... all with variable speed including ... Autoclavable pipette holder. Low battery ...
Inquire...
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Medicine Products: